Torii Pharmaceutical Co., Ltd.
Basic information
- Head office
- 3-4-1 Nihonbashi Honcho, Chuo-ku, Tokyo, Torii Nihonbashi Building
- Chief executive
- Shinya Kondo
- Capital
- 5,190,000,000 JPY (51 100 millionJPY)
- Employees (non-consolidated)
- Employees (consolidated)
- 619 people
- Start date
- 1921-11-01
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
| Keryx Biopharmaceuticals, Inc. | ||||||||
|
|
||||||||
| エフィッシモ キャピタル マネージメント ピーティー イー エルティーディー | ||||||||
|
|
Network
History
Tokuhei Torii established the Western medicine import business 'Utenoya' in Sakaimachi, Yokohama City![]()
Since its founding in 1872, we continue to transform ourselves with flexible ideas and quick actions while valuing the trust we have built.![]()
Established a pharmaceutical testing laboratory and started manufacturing and selling sealed products![]()
Established a collaboration system where sales functions are integrated into our company and research and development functions are concentrated in JT![]()
Launched oral antipruritic agent 'Remitch Capsule' (manufactured and sold by Toray Industries, Inc., approved for sale)![]()
Launched hyperphosphatemia treatment 'Riona Tablets' (manufactured and sold by JT, approved for sale)![]()
Launched allergen immunotherapy drug 'Shidatoren Cedar Pollen Sublingual Solution' for cedar pollen allergy![]()
Launched allergen immunotherapy drug 'Shidacure Cedar Pollen Sublingual Tablets' for cedar pollen allergy![]()
Launch of the externally used Janus kinase (JAK) inhibitor "Collecithum Ointment" (JT manufacturing and sales approval obtained)![]()
Launch of the renal anemia treatment drug "Enaroil Tablets" (JT manufacturing and sales approval obtained)![]()
Launch of the hereditary angioedema attack suppressor plasma kallikrein inhibitor "Oradeo Capsules" (Manufactured and sold by Ophan Pacific Corporation, approval obtained)![]()
Transition from the First Section of the Tokyo Stock Exchange to the Prime Market due to review of market classification![]()
News
There is no news.
Public records
National Tax Agency basic information4010001052143
- Trade name
- 鳥居薬品株式会社
- Trade name (kana)
- トリイヤクヒン
- Name in English
- Corporation type
- 301
- Address
- 〒103-0023 東京都中央区日本橋本町3丁目4番1号
- Postal code
- 1030023
- Prefecture code
- 13
- City code
- 102
- Address outside Japan
- Prefecture in English
- City in English
- Address outside Japan in English
- Corporate number assignment date
- 2015-10-05
- Update date
- 2018-04-16
- Change date
- 2015-10-05
- Registry closure date
- Reason for registry closure
- Successor corporate number
- Details of the change
- Latest record
- 1
- Excluded from search
- 0
- Processing type
- 01
- Correction type
- 1
- Trade name image ID
- Address image ID
- Sequence number
- 1718466
METI gBizINFO4010001052143
- Corporate number
- 4010001052143
- Trade name
- 鳥居薬品株式会社
- Trade name (kana)
- トリイヤクヒン
- Trade name (alphabet)
- Registry closure date
- Reason for registry closure
- Registered address
- 東京都中央区日本橋本町3丁目4番1号
- Postal code
- 1030023
- Prefecture
- 東京都
- Prefecture code
- 13
- City or district
- 中央区
- City code
- 102
- Street address
- 日本橋本町3丁目4番1号
- Organisation type
- 301
- Processing type
- 01
- Correction type
- 1
- Status
- Representative
- 代表取締役社長 近藤 紳雅
- Capital
- 5190000000
- Employees
- 595
- Employees (male)
- Employees (female)
- Business summary
- 医薬品の製造・販売
- Website URL
- http://www.torii.co.jp/
- Year founded
- Business category
- E:製造業
- Date established
- Unified government qualification - grade
- Unified government qualification - business items
- Update date
- 2018-04-16
- Key information
- 4010001052143